Dose reduction, oral application, and order of intake to preserve aspirin antiplatelet effects in dipyrone co-medicated chronic artery disease patients
Dipyrone comedication in aspirin-treated patients is associated with impaired pharmacodynamic response to aspirin (high on-treatment platelet reactivity [HTPR]). Additionally, in small observational studies, an association with impaired outcome has been described. In this uncontrolled, hypothesis-generating study, we aimed to investigate strategies to prevent this drug-drug interaction in patients with coronary artery disease (CAD).
We analyzed pharmacodynamic response to aspirin in 80 dipyrone co-medicated CAD patients. Aspirin antiplatelet effects were measured using arachidonic acid (AA)-induced light-transmission aggregometry (LTA). Platelet reactivity was associated with daily dose, administration form, and frequency. Additionally, we conducted a time-series analysis in patients with HTPR to aspirin with re-evaluation of pharmacodynamic response to aspirin after 5 days.
Patients’ mean age was 75.5 ± 9.8 years. Forty-three (54%) were male, 22 (27.5%) obese, and 38 (47.5%) diabetics. Baseline characteristics, cardiovascular risk factors, comorbidities, comedication, or laboratory parameters did not differ between patients with or without HTPR. HTPR to aspirin occurred in 34 out of 80 patients (42.5%). The incidence of HTPR was associated with dipyrone daily dose (< 1 g/day: HTPR 20% vs. > 3 g/day: HTPR 50%, p > 0.0001) and form of administration (i.v. 87.5% vs. oral 37.5%; p < 0.0001). A strict order of intake (aspirin 30 min prior to dipyrone) restored aspirin antiplatelet effects in all patients (HTPR before 100% vs. HTPR after 0%, p = 0.0002).
This study shows that dipyrone should be used with caution in aspirin-treated patients. If dipyrone seems indispensable, the lowest effective dose and a strict order of intake seem favorable.
KeywordsAggregation Aspirin Comedication Dipyrone Platelet activation Platelet inhibition
Angiotensine converting enzyme
- AT II
Coronary bypass grafting
Chronic obstructive pulmonary disease
Chronic artery disease
Chronic kidney disease
Glomerular filtration rate
High density lipoprotein
High on-treatment platelet reactivity
Light transmission aggregometry
Major adverse cardiac and cerebrovascular events
Maximum of aggregation
Percutaneous coronary intervention
The authors thank Kirsten Bartkowski for experimental support.
L.D., T.P., and A.A. designed the study, analyzed, and interpreted data and wrote the manuscript. D.N., S.Z., C.H., R.M., and P.M. collected data and revised the manuscript. A.P., T.H., M.K., T.Z., B.L., M.G., and Y.P. supervised the study and revised the manuscript.
This work was supported by the Forschungskommission of the Medical Faculty of the Heinrich Heine University (No. 46-2016, to L.D., No. 16-2014 to A.P.).
Compliance with ethical standards
The study conformed to the Declaration of Helsinki and was approved by the University of Düsseldorf Ethics Committee.
Conflict of interest
The authors declare that they have no conflicts of interest.
- 1.Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C (2006) Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 113(25):2906–2913CrossRefGoogle Scholar
- 4.Schwabe UP (2014) Deutscher Arzneiverordnungsreport 2014: Aktuelle Daten, Kosten, Trends und Kommentare. Dieter PaffrathGoogle Scholar
- 5.McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur J Heart Fail 14(8):803–869CrossRefGoogle Scholar
- 8.Lamberts M, Lip GY, Hansen ML, Lindhardsen J, Olesen JB, Raunso J et al (2014) Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med 161(10):690–698CrossRefGoogle Scholar
- 9.Lamberts M, Fosbol EL, Olsen AM, Hansen ML, Folke F, Kristensen SL et al (2013) Ongoing treatment with non-steroidal anti-inflammatory drugs at time of admission is associated with poorer prognosis in patients with first-time acute myocardial infarction. Int J Cardiol 168(2):832–837CrossRefGoogle Scholar
- 10.Schmidt M, Lamberts M, Olsen AM, Fosboll E, Niessner A, Tamargo J et al (2016) Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for cardiovascular pharmacotherapy of the European Society of Cardiology. Eur Heart J 37(13):1015–1023CrossRefGoogle Scholar
- 12.Gerd Glaeske CS (2015) BARMER GEK Arzneimittelreport 2015. Barmer GEKGoogle Scholar
- 20.Polzin A, Richter S, Schror K, Rassaf T, Merx MW, Kelm M et al (2015) Prevention of dipyrone (metamizole) induced inhibition of aspirin antiplatelet effects. Thromb Haemost 114(1):87–95Google Scholar
- 27.Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ten Berg JM, Hackeng CM (2010) High on-aspirin platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive platelet function tests is associated with the occurrence of atherothrombotic events. J Thromb Haemost 8(10):2140–2148CrossRefGoogle Scholar
- 35.Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Hadamitzky M, Merkely B, Kiss RG, Komócsi A, Dézsi CA, Holdt L, Felix SB, Parma R, Klopotowski M, Schwinger RHG, Rieber J, Huber K, Neumann FJ, Koltowski L, Mehilli J, Huczek Z, Massberg S, Parma R, Parma Z, Lesiak M, Komosa A, Huczek Z, Koltowski L, Kowara M, Rymuza B, Klopotowski M, Malek L, Aradi D, Veress G, Dézsi AD, Merkely B, Lux Á, Kiss RG, Papp J, Kovács A, Dézsi CA, Amer S, Ruzsa Z, Róna S, Komócsi A, Ili R, Ungi I, Nagy F, Zweiker R, Tóth-Gayor G, Huber K, Haller P, von Scheidt W, Blüthgen A, Neumann FJ, Trenk D, Leggewie S, Kreider-Stempfle HU, Remp T, Kara K, Mügge A, Wutzler A, Fichtlscherer S, Zeiher AM, Seeger F, Hinterseer M, König A, Lederle S, Jacobshagen C, Czepluch F, Maier L, Schillinger W, Sossalla S, Hummel A, Felix S, Karakas M, Sydow K, Rudolph T, Halbach M, Gori T, Münzel T, May A, Gerstenberg CM, Pilecky D, Rieber J, Deichstetter M, Sibbing D, Mehilli J, Gross L, Kääb S, Löw A, Orban M, Orban M, Sattler S, Deuschl S, Teupser D, Holdt L, Mudra H, Räder T, Schütz T, Vahldiek F, Divchev D, Ince H, Nienaber CA, Radunski H, Boekstegers P, Horstkotte J, Mueller R, Geisler T, Müller K, Schwinger R, Rasp O (2017) Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. In: Lancet, vol 390, pp 1747–1757Google Scholar
- 36.Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Muller U et al (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on Clopidogrel to guide alternative therapy with Prasugrel) study. J Am Coll Cardiol 59(24):2159–2164CrossRefGoogle Scholar
- 38.Cayla G, Cuisset T, Silvain J, Leclercq F, Manzo-Silberman S, Saint-Etienne C, Delarche N, Bellemain-Appaix A, Range G, el Mahmoud R, Carrié D, Belle L, Souteyrand G, Aubry P, Sabouret P, du Fretay XH, Beygui F, Bonnet JL, Lattuca B, Pouillot C, Varenne O, Boueri Z, van Belle E, Henry P, Motreff P, Elhadad S, Salem JE, Abtan J, Rousseau H, Collet JP, Vicaut E, Montalescot G (2016) Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet 388(10055):2015–2022CrossRefGoogle Scholar
- 39.Collet JP, Cayla G, Cuisset T, Elhadad S, Range G, Vicaut E et al (2011) Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am Heart J 161(1):5–12 e5CrossRefGoogle Scholar
- 40.Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ (2011) Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation 124(10):1132–1137CrossRefGoogle Scholar
- 41.Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A et al (2017) ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J:2017Google Scholar